Terms: = Pancreatic cancer AND SDHC, CYBL, 6391, ENSG00000143252, SDH3, PGL3, QPS1, CYB560 AND Prognosis
3 results:
1. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer.
Song Z; Ren H; Gao S; Zhao X; Zhang H; Hao J
Tumour Biol; 2014 Nov; 35(11):11319-28. PubMed ID: 25119596
[TBL] [Abstract] [Full Text] [Related]
3. The hypoxia-inducible factor-1 regulates the microRNA185 expression through binding to hypoxia response elements sequence 2.
Song Z; Ren H; Gao S; Zhao T; Wang X; Zhang S; Zhao X; Jia L; Sun J; Hao J
Med Oncol; 2013 Dec; 30(4):756. PubMed ID: 24198204
[TBL] [Abstract] [Full Text] [Related]
